Biocartis, a developer of molecular diagnostic (MDx) systems, has appointed Nayan Gregory Parekh as the company's new chief executive officer (CEO).

Since April 2011, Parekh served as an executive director and brings pharmaceutical and biotechnology industry experience to Biocartis.

Previously he served at a healthcare investment – New Rhein Healthcare – where he was one of the founding partners.

At Novartis, Parekh seved as a head of corporate development and spent six years where he led Novartis investments in Diagnostics, Eye Care, Generics and Vaccines as well as certain emerging markets such as China, Saudi Arabia, Brazil and Russia .

Prior to joining Novartis in 2004, where he was also a member of the Novartis Group Finance Committee, he spent ten years in investment banking, primarily focusing on the pharmaceutical and biotechnology sectors.

Biocartis executive chairman Rudi Pauwelssaid Parekh’s industry and financial experience combined with his knowledge of the company made him to lead the next exciting stage of Biocartis’ development.

Biocartis CEO Nayan Gregory Parekh said the company is well placed to launch various molecular diagnostics systems that will deliver high-quality data in a timely manner and improve healthcare outcomes.